

REMARKS

Claims 1-10 are active in the present application. Claims 3-8 and 10 have been amended to remove multiple dependencies. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238



22850

(703) 413-3000
NFO/DJP/smi

I:\atty\SUKOS\217415US-pr.wpd

Marked-Up Copy

Serial No:

Amendment Filed on:

12-31-01

IN THE CLAIMS

Please amend the claims as follows.

--3. (Amended) The citrullinated polypeptide as claimed in [either of claims 1 and 2, characterized in that] claim 1, wherein said vertebrate fibrin is a mammalian fibrin, preferably a human fibrin.

4. (Amended) The use of a polypeptide as claimed in [any one of claims 1 to 3] claim 1, for diagnosing rheumatoid arthritis, *in vitro*.

5. (Amended) An antigenic composition for diagnosing the presence of rheumatoid arthritis-specific autoantibodies in a biological sample, characterized in that it contains at least one citrullinated polypeptide as claimed in [any one of claims 1 to 3] claim 1, optionally labeled with and/or conjugated to a carrier molecule.

6. (Amended) A method for detecting rheumatoid arthritis specific autoantibodies in a biological sample, which method is characterized in that it comprises:

bringing said biological sample into contact with at least one polypeptide as claimed in [any one of claims 1 to 3] claim 1, under conditions which allow the formation of an antigen/antibody complex with the rheumatoid arthritis-specific autoantibodies possibly present;

detecting, by any suitable means, the antigen/antibody complex possibly formed.

7. (Amended) A kit for detecting rheumatoid arthritis-specific autoantibodies in a biological sample, characterized in that it comprises at least one polypeptide as claimed in [any one of claims 1 to 3] claim 1, and also buffers and reagents suitable for constituting a reaction medium which allows the formation of an antigen/antibody complex, and/or means for detecting said antigen/antibody complex.

8. (Amended) The use of a citrullinated polypeptide as claimed in [any one of claims 1 to 3] claim 1, for producing a medicinal product.

10. (Amended) A pharmaceutical composition, characterized in that it contains, as active principle, at least one citrullinated polypeptide as claimed in [any one of claims 1 to 3] claim 1--

2020090766767001